Incannex Approves 1-for-30 Reverse Stock Split

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Feb 25 2026

0mins

IXHL+19.16%

Should l Buy IXHL?

Source: Newsfilter

Reverse Split Approval: Incannex Healthcare Inc.'s board has approved a 1-for-30 reverse stock split aimed at increasing the per-share trading price to meet Nasdaq's minimum bid price requirement, thereby ensuring the company's continued listing on the exchange.
Shareholder Meeting Endorsement: The reverse split plan was approved at a special shareholder meeting on May 27, 2025, and is set to take effect at 4:01 PM ET on February 26, 2026, marking a significant adjustment in the company's capital market strategy.
Change in Share Count: Post-split, the number of outstanding shares will decrease from approximately 358,329,368 to about 11,944,313, while the total authorized shares will remain unchanged, impacting the ownership structure of the company.
Shareholder Rights Protection: For shareholders holding fractional shares, the reverse split will automatically adjust their holdings to whole shares, ensuring that no shareholder suffers a loss due to the split ratio, reflecting the company's commitment to protecting shareholder interests.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy IXHL?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on IXHL

About IXHL

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Incannex Implements Reverse Stock Split to Support Compliance

3 hours agostocktwits

Reverse Stock Split: Incannex executed a 1-for-30 reverse stock split on February 26, reducing outstanding shares from 358 million to approximately 11.9 million, which is expected to enhance per-share price and investor confidence as the company aims to meet Nasdaq compliance requirements.
Regulatory Progress: The company's lead sleep apnea drug, IHL-42X, received Fast Track designation from the FDA in December, following positive Phase 2 RePOSA study results that demonstrated up to an 83% reduction in breathing interruptions, potentially accelerating its clinical development and market acceptance.
Strong Financial Position: Incannex reported over $70 million in cash at the beginning of 2026, providing a solid operating runway into 2027, which supports its clinical pipeline and reflects positively on investor confidence following two successful Phase 2 clinical readouts in 2025.
Bullish Market Sentiment: On Stocktwits, retail sentiment for IXHL is bullish with high message volume, as users express intentions to increase their positions ahead of the Nasdaq compliance window, indicating strong anticipation for significant news announcements.

Incannex Healthcare to Implement 1-for-30 Reverse Stock Split

Feb 25 2026seekingalpha

Reverse Stock Split Announcement: Incannex Healthcare has announced a 1-for-30 reverse stock split effective February 26, 2026, aimed at increasing its per-share trading price to comply with Nasdaq's minimum bid price requirement for continued listing.
Share Count Reduction: The reverse split will reduce the outstanding shares from approximately 358.3 million as of February 20, 2026, to about 11.9 million, while the total authorized share count will remain unchanged, significantly enhancing the per-share value.
Trading Timeline: The split-adjusted shares are expected to begin trading on the Nasdaq Capital Market on February 27, 2026, under the existing ticker symbol “IXHL,” which may help boost market visibility and investor interest in the company.
Market Reaction: Following the announcement of the reverse split, IXHL's stock price fell by 37.73% to $0.1706, indicating market concerns regarding the company's current financial health, which could impact investor confidence.

Incannex Healthcare Announces 1-for-30 Reverse Stock Split

Feb 25 2026stocktwits

Reverse Split Decision: Incannex Healthcare's board approved a 1-for-30 reverse stock split, previously sanctioned by shareholders on May 27, 2025, aimed at boosting share price to meet Nasdaq listing requirements.
Legal Effect Timing: The reverse split will take legal effect at 4:01 p.m. ET on February 26, 2026, which is expected to impact the company's stock liquidity and potentially attract more investor interest.
Trading Change Notification: Following the reverse split, Incannex common shares will begin trading on the Nasdaq Capital Market under a new CUSIP number, 45333F 208, on February 27, while retaining the ticker symbol ‘IXHL’, ensuring easy identification for investors.
Stock Price Reaction: Following the announcement of the reverse split, Incannex stock tumbled over 32% on Wednesday morning, reflecting a negative market reaction to the decision that could affect the company's future financing capabilities and market confidence.